Atividades antinociceptiva e antiinflamatória da lectina da alga marinha verde Caulerpa cupressoides (Vahl) C. Agardh var. lycopodium em animais

• Autor(a) principal: Vanderlei, Edfranck de Sousa Oliveira
• Data de Publicação: 2008
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Institucional da Universidade Federal do Ceará (UFC)
• Texto Completo: http://www.repositorio.ufc.br/handle/riufc/10457
• topic: Bioquímica; Alga marinha; Lectina de alga marinha; Migração de leucócitos

The search of new alternative compounds in the control of the pain and inflammation, with minima collateral effects, it has been aroused from marine algae. The aim of this work was to investigate the potential antinociceptive and anti-inflammatory of the lectin from the green marine alga Caulerpa cupressoides (Vahl) C. Agardh var lycopodium (CcL) in animals. The CcL, presenting haemagglutinating activity against trypsin-treated erythrocytes from rabbit, was purified by application of crude extract on ion exchange chromatography on DEAE-cellulose followed by affinity chromatography on Sephadex G-100 column. To proceed, it was used in the nociception and inflammation assays, using male Swiss mice and male Wistar rats, respectively. CcL was administered 30 min before each nocigenic challenge, that is, before the injection i.p of acetic acid 0.8% (10 l/ml), of the intraplantar injection of 1% formalin (20 L/paw) or of the Hot Plate test (51±1 ºC), and compared to non treated animals or to pre-treated by Indomethacin or Morphine, both at 5 mg/kg; s.c. It was observed that the LCc (3, 9 or 27 mg/kg) reduced significantly the number of writhes induced by acetic acid 37.2%; 53.5% e 86.0%, respectively. CcL (27 mg/kg) also reduced (p<0.05) the 1st phase (neurogenic) and the 2nd phase (inflammatory) observed after administration of the formalin (45.3% and 86.3%, respectively). However, the CcL (27 mg/kg) was not capable to reduce the nociception evaluated by Hot Plate test, compared to morphine. The antinociceptive effects were abolished when the CcL was pre-incubated with mucin (2 mg/ml), inhibitory glycoprotein of its haemagglutinating activity. Therefore, it is suggested that the antinociceptive activity of the CcL can be predominant by inhibition of peripheric mechanisms. After this, was realized the assays of neutrophil migration for peritoneal cavity by Carrageenan (Cg-type λ; 700 µg/cavity or paw), where was observed that the administration of the CcL (9 mg/kg) 30 min before Cg reduced the neutrophil counts significantly by 65.9%. Finally, the CcL (9 mg/kg) was administered daily in male mice for 7 days and in the 8th, blood samples were collected for and transaminases (TGO and TGP) dosages, and organs remotion to evaluate the of the organ weight /body weight relation. It was observed that CcL not caused hepatic or renal alterations, because it was not determined significant changes in the activities of TGO (Saline=29,44±3,193; CcL=36,00±21,98 U/l) and TGP (Saline=13,59±3,373; CcL=17,64±2,676 U/l) and urea levels (Saline=224,3±10,84; CcL=270,0±24,00 U/l). In addition, it was not determined significant variation on the wet weight of the organs: liver (Saline=5,23±0,195; CcL=6,02±0,100), kidney (Saline=0,840±0,015; CcL=0,851±0,065) and heart (Saline=0,568±0,055; CcL=0,639± 0,039). In summary, we conclude that the CcL has peripheral antinociceptive and anti-inflammatory properties and may be an important tool and candidate for new complementary studies.